Cargando…

Proposed Therapies for Pantothenate-Kinase-Associated Neurodegeneration

Multiple approaches to therapy have been proposed for the rare inherited neurodegenerative disease associated with mutations in the PANK2 gene, called pantothenate-kinase-associated neurodegeneration (PKAN). Penetration of the blood-brain barrier for treatment of a central nervous system (CNS) disor...

Descripción completa

Detalles Bibliográficos
Autor principal: Jackowski, Suzanne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6537486/
https://www.ncbi.nlm.nih.gov/pubmed/31205425
http://dx.doi.org/10.1177/1179069519851118
_version_ 1783422022237290496
author Jackowski, Suzanne
author_facet Jackowski, Suzanne
author_sort Jackowski, Suzanne
collection PubMed
description Multiple approaches to therapy have been proposed for the rare inherited neurodegenerative disease associated with mutations in the PANK2 gene, called pantothenate-kinase-associated neurodegeneration (PKAN). Penetration of the blood-brain barrier for treatment of a central nervous system (CNS) disorder is a major challenge in drug discovery. Evaluation of the biochemistry and medicinal chemistry of the proposed therapies reveals potential liabilities among several compounds under consideration for clinical development.
format Online
Article
Text
id pubmed-6537486
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-65374862019-06-14 Proposed Therapies for Pantothenate-Kinase-Associated Neurodegeneration Jackowski, Suzanne J Exp Neurosci Commentary Multiple approaches to therapy have been proposed for the rare inherited neurodegenerative disease associated with mutations in the PANK2 gene, called pantothenate-kinase-associated neurodegeneration (PKAN). Penetration of the blood-brain barrier for treatment of a central nervous system (CNS) disorder is a major challenge in drug discovery. Evaluation of the biochemistry and medicinal chemistry of the proposed therapies reveals potential liabilities among several compounds under consideration for clinical development. SAGE Publications 2019-05-23 /pmc/articles/PMC6537486/ /pubmed/31205425 http://dx.doi.org/10.1177/1179069519851118 Text en © The Author(s) 2019 http://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Commentary
Jackowski, Suzanne
Proposed Therapies for Pantothenate-Kinase-Associated Neurodegeneration
title Proposed Therapies for Pantothenate-Kinase-Associated Neurodegeneration
title_full Proposed Therapies for Pantothenate-Kinase-Associated Neurodegeneration
title_fullStr Proposed Therapies for Pantothenate-Kinase-Associated Neurodegeneration
title_full_unstemmed Proposed Therapies for Pantothenate-Kinase-Associated Neurodegeneration
title_short Proposed Therapies for Pantothenate-Kinase-Associated Neurodegeneration
title_sort proposed therapies for pantothenate-kinase-associated neurodegeneration
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6537486/
https://www.ncbi.nlm.nih.gov/pubmed/31205425
http://dx.doi.org/10.1177/1179069519851118
work_keys_str_mv AT jackowskisuzanne proposedtherapiesforpantothenatekinaseassociatedneurodegeneration